Attached files
| file | filename |
|---|---|
| EX-31.2 - EX-31.2 - Axsome Therapeutics, Inc. | axsm-20171231ex312f128f1.htm |
| EX-32.2 - EX-32.2 - Axsome Therapeutics, Inc. | axsm-20171231ex322d61d77.htm |
| EX-32.1 - EX-32.1 - Axsome Therapeutics, Inc. | axsm-20171231ex321db8236.htm |
| EX-31.1 - EX-31.1 - Axsome Therapeutics, Inc. | axsm-20171231ex311b47a55.htm |
| 10-K - 10-K - Axsome Therapeutics, Inc. | axsm-20171231x10k.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statements:
|
· |
Registration Statement (Form S-8 No. 333-217002) pertaining to the Axsome Therapeutics, Inc. 2015 Omnibus Incentive Compensation Plan, |
|
· |
Registration Statement (Form S-8 No. 333-208579) pertaining to the Axsome Therapeutics, Inc. 2015 Omnibus Incentive Compensation Plan, and |
|
· |
Registration Statement (Form S-3 No. 333-214859) of Axsome Therapeutics, Inc. and in the related Prospectus; |
of our report dated March 7, 2018, with respect to the consolidated financial statements of Axsome Therapeutics, Inc. included in this Annual Report (Form 10-K) of Axsome Therapeutics, Inc. for the year ended December 31, 2017.
|
|
/s/ Ernst & Young LLP |
|
|
|
|
New York, NY |
|
|
March 7, 2018 |
|